When Alalfy et al. (2018) [1] investigated the effectiveness of intrauterine misoprostol during cesarean delivery for the prevention of primary postpartum hemorrhage, they compared intrauterine misoprostol together with oxytocin versus oxytocin alone and reported that combining intrauterine misoprostol (400 mcg) with oxytocin infusion was valuable for lowering postpartum blood loss and postpartum hemorrhage during elective CS delivery. Here, OXT is linked to hemorrhage.